{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Is bluebird bio, Inc. technically bullish or bearish?
As of May 12, 2025, the technical trend is mildly bearish, with mixed signals from key indicators suggesting a weak bearish outlook.
Who are in the management team of bluebird bio, Inc.?
As of March 2022, the management team of bluebird bio, Inc. includes Daniel Lynch (Independent Chairman), Nick Leschly (CEO), Ramy Ibrahim, Denice Torres, John Agwunobi, Wendy Dixon, and David Schenkein (all Independent Directors). They oversee the company's strategic direction and operations.
What does bluebird bio, Inc. do?
bluebird bio, Inc. is a clinical-stage biotechnology company focused on gene therapies for severe diseases and cancer, with a market cap of $48.41 million and recent net sales of $39 million. The company reported a net loss of $29 million in its latest quarterly results.
How big is bluebird bio, Inc.?
As of Jun 03, bluebird bio, Inc. has a market capitalization of 48.41 million and reported net sales of 103.94 million with a net profit of -199.98 million over the latest four quarters. Shareholder's funds are at -31.53 million, and total assets amount to 460.23 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
